Gravelle Pauline, Do Catherine, Franchet Camille, Mueller Sabina, Oberic Lucie, Ysebaert Loïc, Larocca Luigi Maria, Hohaus Stefan, Calmels Marie-Noëlle, Frenois François-Xavier, Kridel Robert, Gascoyne Randy D, Laurent Guy, Brousset Pierre, Valitutti Salvatore, Laurent Camille
Centre de Physiopathologie de Toulouse Purpan, INSERM U1043, Toulouse, France; Département de Pathologie, Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse, France; Laboratoire d'Excellence "TOUCAN," Toulouse, France; Program Hospitalo-Universitaire en Cancérologie "CAPTOR," Toulouse, France; CALYM Carnot Institute, Pierre-Bénite, France.
Institute for Cancer Genetics, Columbia University , New York, USA.
Oncoimmunology. 2016 Aug 24;5(10):e1224044. doi: 10.1080/2162402X.2016.1224044. eCollection 2016.
Upregulation of T cell immunoglobulin-3 (TIM-3) has been associated with negative regulation of the immune response in chronic infection and cancer, including lymphoma. Here, we investigated the possible correlation between TIM-3 expression by cytotoxic T cells (CTL) from follicular lymphoma (FL) biopsies and their functional unresponsiveness that could limit the favorable impact of CTL on disease progression. We report a high percentage of CD8TIM-3T cells in lymph nodes of FL patients. When compared to their CD8TIM-3 counterparts, CD8TIM-3 T cells exhibited defective cytokine production following TCR engagement. Furthermore, CD8TIM-3 T cells display markers of lytic granule release and remain unresponsive to further TCR-induced activation of the lytic machinery. Although confocal microscopy showed that TIM-3 expression on CD8 T cells correlated with minor alterations of immunological synapse, a selective reduction of ERK signaling in CD8TIM-3T cells was observed by phospho-flow analysis. Finally, short relapse-free survival despite rituximab(R)-chemotherapy was observed in patients with high content of TIM-3 cells and a poor infiltrate of granzyme B T cells in FL lymph nodes. Together, our data indicate that, besides selective TCR early signaling defects, TIM-3 expression correlates with unresponsiveness of CD8 T cells in FL. They show that scores based on the combination of exhaustion and cytolytic markers in FL microenvironment might be instrumental to identify patients at early risk of relapses following R-chemotherapy.
T细胞免疫球蛋白3(TIM-3)的上调与慢性感染和癌症(包括淋巴瘤)中免疫反应的负调控相关。在此,我们研究了来自滤泡性淋巴瘤(FL)活检组织的细胞毒性T细胞(CTL)中TIM-3表达与其功能无反应性之间的可能关联,这种无反应性可能会限制CTL对疾病进展的有利影响。我们报告FL患者淋巴结中CD8⁺TIM-3⁺T细胞的比例很高。与CD8⁺TIM-3⁻对应细胞相比,CD8⁺TIM-3⁺T细胞在TCR激活后细胞因子产生存在缺陷。此外,CD8⁺TIM-3⁺T细胞显示出溶细胞颗粒释放的标志物,并且对TCR诱导的溶细胞机制的进一步激活仍无反应。尽管共聚焦显微镜显示CD8⁺T细胞上的TIM-3表达与免疫突触的轻微改变相关,但通过磷酸化流式分析观察到CD8⁺TIM-3⁺T细胞中ERK信号传导选择性降低。最后,在FL淋巴结中TIM-3⁺细胞含量高且颗粒酶B⁺T细胞浸润差的患者中,尽管接受了利妥昔单抗(R)化疗,但无进展生存期较短。总之,我们的数据表明,除了选择性TCR早期信号缺陷外,TIM-3表达与FL中CD8⁺T细胞的无反应性相关。它们表明,基于FL微环境中耗竭和溶细胞标志物组合的评分可能有助于识别接受R化疗后早期复发风险的患者。